Ipamorelin vs Sermorelin: Two Ways to Ask the Pituitary for Growth Hormone

Growth hormone is not released in a steady stream. It comes out in pulses, mostly at night, and each pulse is the result of a negotiation between signals that say “release” and a signal that says “wait”. Ipamorelin and Sermorelin both join that negotiation on the “release” side. But they speak for completely different parties. Sermorelin carries the message of the brain’s own growth hormone releasing hormone. Ipamorelin borrows the receptor of ghrelin, the hunger hormone that turned out to have a second job.

That is why the two are compared so often, and why “which is better?” is the wrong first question. The useful question is which signal a piece of research is actually trying to study. This guide explains where each compound came from, how each one works, what the published studies measured, and where they overlap. Ipamorelin and Sermorelin are supplied by Crown Peptides strictly for laboratory research use only, and everything below is written for readers interested in the science.

Release, Wait, and a Second Voice: How the Pituitary Decides

Growth hormone is made by cells called somatotrophs in the front part of the pituitary gland. They store it and let it out in bursts. Three signals decide when those bursts happen.

The main “release” signal: GHRH

Growth hormone releasing hormone (GHRH) is made in the hypothalamus and travels a very short distance to the pituitary. It binds the GHRH receptor on somatotrophs and tells them to release growth hormone and to make more of it. This is the signal Sermorelin copies.

The “wait” signal: somatostatin

Somatostatin is the brake. When it is high, somatotrophs hold their growth hormone back even if GHRH is present. The rhythm of growth hormone pulses comes largely from GHRH and somatostatin taking turns.

The second voice: ghrelin

In the 1980s and 1990s, chemists built small synthetic peptides that released growth hormone through a receptor nobody could yet explain. That receptor was later named the growth hormone secretagogue receptor (GHSR-1a), and its natural partner turned out to be ghrelin, a hormone made mainly in the stomach. Ghrelin amplifies growth hormone pulses and pushes back against somatostatin. This is the signal Ipamorelin copies.

So the two peptides are not rivals for the same lock. They work on two different locks on the same cell, which is why researchers often study them side by side, and sometimes together.

Thinking in pulses

This is the part most people miss when they first read about growth hormone peptides. Neither compound simply “adds” growth hormone. Each one changes the shape of the pulses the pituitary is already producing. A bigger pulse at the right moment, followed by a return to low levels, is very different biologically from a steady flood. Liver, muscle and fat cells all respond to the pattern of growth hormone as well as the amount, and many researchers consider the pulsed pattern central to its effects. That is why the comparison between Ipamorelin and Sermorelin is really a comparison between two ways of shaping a pulse.

Sermorelin: The Smallest Piece of GHRH That Still Works

Natural human GHRH is 44 amino acids long. Researchers in the 1980s discovered that the full chain is not needed. The first 29 amino acids, with an amidated end, keep the full biological activity of the hormone. That fragment is Sermorelin, sometimes written GHRH(1-29)NH2. A 1999 review in BioDrugs described it as “the shortest synthetic peptide with full biological activity of GHRH” (PMID: 18031173).

From a tumour to a fragment

GHRH itself was only identified in 1982. Two research teams isolated it from rare pancreatic tumours that were producing so much of the hormone that the patients’ pituitaries were pouring out growth hormone. Within a short time, chemists had made the hormone synthetically and started cutting it down to find the smallest piece that still worked. The answer, the first 29 amino acids, became Sermorelin. It was one of the first examples of a hormone being trimmed to its working core and turned into a usable research and clinical tool.

A real medicine, then a quiet exit

Sermorelin was developed as a medicine under the brand name Geref. It was used as a diagnostic test, because a pituitary that responds to Sermorelin is a pituitary that can make growth hormone, and it was used to treat some children with idiopathic growth hormone deficiency. The same review reported sustained increases in height velocity over 12 months of treatment in prepubertal children, with data in a few children suggesting the effect held for up to 36 months (PMID: 18031173). The branded product was later withdrawn from the US market for commercial reasons rather than safety concerns, which is why Sermorelin today is mainly a research compound.

The ageing studies

Because Sermorelin works through the body’s own feedback system, it attracted interest as a gentler way to study the decline in growth hormone that comes with age. Two 1997 trials are the most cited.

Older men, six weeks

In a study in Metabolism, 11 healthy men aged 64 to 76 with low starting IGF-1 levels received nightly GHRH(1-29) for six weeks. Night-time growth hormone release rose, along with the size of growth hormone peaks, while the number of pulses stayed the same. IGF-1 did not change. Two of six strength measures and one endurance test improved, and body composition did not change (PMID: 9005976). The authors concluded that a single nightly dose was less effective than more frequent dosing, a direct consequence of how quickly the molecule is cleared.

Older men and women, sixteen weeks

A larger study in the Journal of Clinical Endocrinology and Metabolism gave a closely related analogue ([Nle27]GHRH(1-29)NH2) nightly for 16 weeks to 19 adults aged 55 to 71. IGF-1 rose, skin thickness increased in both sexes, and lean body mass and insulin sensitivity improved in men only. The only adverse effect reported was a temporary rise in blood lipids that resolved by the end of the study (PMID: 9141536).

The pattern across these studies is consistent. Sermorelin raises growth hormone in a way that keeps the body’s natural pulses intact, but its short life in the bloodstream limits how much it can achieve with infrequent dosing. That limitation is exactly what later GHRH analogues such as Tesamorelin and CJC-1295 (With DAC) were designed to solve. For the fuller Sermorelin story, see our Sermorelin research guide.

Ipamorelin: The Ghrelin Mimic That Left Cortisol Alone

Ipamorelin came out of a medicinal chemistry programme at Novo Nordisk in the 1990s. It is a pentapeptide, just five amino acids long, with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Several of those building blocks are unnatural, including two D-amino acids and the unusual residue Aib, which make the molecule harder for enzymes to break down.

The drugs that came before the hormone

Ipamorelin’s family has one of the strangest origin stories in endocrinology. In the late 1970s, the American endocrinologist Cyril Bowers was working with small synthetic peptides modelled on met-enkephalin, a natural opioid peptide, and noticed that some of them made the pituitary release growth hormone. Refining that series produced GHRP-6, described in the mid-1980s. The odd thing was that nobody knew what GHRP-6 was actually acting on. In 1996, a team at Merck finally cloned its receptor, which they called the growth hormone secretagogue receptor. Only in 1999 did Japanese researchers find the natural hormone that receptor was built for: ghrelin, made mainly in the stomach. In other words, the synthetic keys were made years before anyone found the natural one. Ipamorelin arrived at the end of that journey, as a refined key that opens the growth hormone door without also opening the stress-hormone one.

“The first selective growth hormone secretagogue”

The 1998 paper that introduced Ipamorelin in the European Journal of Endocrinology gave it that title for a specific reason (PMID: 9849822). Earlier growth hormone releasing peptides, such as GHRP-6 and GHRP-2, released growth hormone well, but they also raised ACTH and cortisol, the stress hormones. Ipamorelin did not.

What the Novo Nordisk team measured

In rats, Ipamorelin released growth hormone with a potency and efficacy comparable to GHRP-6. In pigs, it again matched GHRP-6. None of the compounds tested changed FSH, LH, prolactin or TSH. But while GHRP-6 and GHRP-2 both raised ACTH and cortisol, Ipamorelin did not raise them meaningfully above the levels seen with GHRH itself, even at doses more than 200 times higher than those needed to release growth hormone (PMID: 9849822). That clean profile is the reason Ipamorelin became the reference ghrelin-receptor peptide in research.

The first human numbers

Ipamorelin’s behaviour in people was mapped in a 1999 study in Pharmaceutical Research. Healthy men received Ipamorelin by infusion at five different dose levels, eight men per level. Each dose produced a single, clean episode of growth hormone release that peaked at about 40 minutes and then fell back to negligible levels. Ipamorelin itself had a terminal half-life of about two hours, and its blood levels rose in proportion to the dose (PMID: 10496658). That single, well-defined pulse is exactly what makes it a precise research tool: researchers know when the response will come and when it will be over.

The gut connection

Because ghrelin also speeds up the gut, Ipamorelin was tested as a treatment for postoperative ileus, the temporary shutdown of the bowel after abdominal surgery. In rats, repeated dosing increased stool output, food intake and weight gain after surgery (PMID: 19289567), and a separate rat study found faster stomach emptying (PMID: 27186127).

The human test was more sobering. A phase 2 trial in 114 surgical patients found Ipamorelin well tolerated, but there was no significant difference from placebo in the main or secondary efficacy measures. The median time to the first tolerated meal was 25.3 hours with Ipamorelin and 32.6 hours with placebo, a difference that did not reach statistical significance (PMID: 25331030). Ipamorelin was never approved as a medicine. Our Ipamorelin research guide covers its background in more depth.

Ipamorelin vs Sermorelin: Side by Side

Which receptor?

Sermorelin binds the GHRH receptor. Ipamorelin binds the ghrelin receptor, GHSR-1a. They are different proteins that sit on the same somatotroph cells.

How big?

Sermorelin is 29 amino acids, a direct copy of the front of a natural hormone. Ipamorelin is five amino acids, a designed molecule built from unusual building blocks. Size affects almost everything else: how each is made, how each is tested and how each behaves in solution.

How long does each last?

Both are short-acting compared with modified GHRH analogues. Sermorelin is cleared within minutes, mainly because an enzyme called DPP-4 clips its first two amino acids. Ipamorelin’s unnatural residues give it more resistance to enzymes, but it is still a short-acting compound that produces a growth hormone pulse rather than a sustained rise.

What does each do to the pulse?

Sermorelin increases the size of growth hormone peaks while keeping their natural timing, as the 1997 Metabolism study showed. Ipamorelin produces its own pulse through a different route and can partly override the somatostatin brake, which GHRH cannot do on its own.

How selective is each?

Sermorelin is inherently selective, because the GHRH receptor is mainly found on somatotrophs. Ipamorelin’s selectivity was its headline finding: unlike older ghrelin-receptor peptides, it left ACTH, cortisol and prolactin alone in the original studies.

What is the human record?

Sermorelin was a licensed medicine for children and was studied in older adults. Ipamorelin reached a phase 2 surgical trial that did not meet its goals. Both have meaningful human data, but of different kinds.

Which One Fits a Research Question?

When Sermorelin fits

Sermorelin is the natural choice when the question is about the GHRH pathway itself: how somatotrophs respond to their own releasing hormone, how that response changes with age, or how a pituitary that is still working reacts to stimulation. Its long clinical history as a diagnostic tool makes it a well-understood reference compound.

When Ipamorelin fits

Ipamorelin fits when the question is about the ghrelin receptor: growth hormone release through a second pathway, the interaction with somatostatin, or gut motility. Its selectivity also makes it useful when a study needs to separate growth hormone effects from stress hormone effects, because a cleaner compound means fewer confounding signals.

Why they are so often studied together

The two pathways reinforce each other. GHRH tells somatotrophs to release growth hormone, while ghrelin-receptor agonists amplify the response and lean against the somatostatin brake. Studies of the growth hormone axis have long shown that combining the two kinds of signal produces a larger response than either alone. That idea is the basis of the CJC-1295 (No DAC) + Ipamorelin (Blend), which pairs Ipamorelin with a modified, more stable version of the same 29-amino-acid GHRH fragment that Sermorelin is built from. We explain that pairing in CJC-1295 (No DAC) and Ipamorelin: the two-pathway approach.

The Technical Breakdown: Two Signalling Routes in One Cell

This section is for readers who want the cell biology.

The GHRH route

The GHRH receptor is a G protein-coupled receptor linked to Gs. When Sermorelin binds, Gs activates adenylate cyclase, cyclic AMP rises, and protein kinase A switches on. That does two things: it opens calcium channels so stored growth hormone is released, and it activates the transcription factor CREB, which increases production of new growth hormone and of Pit-1, a factor that keeps somatotrophs healthy. Somatostatin works against this route by lowering cyclic AMP.

The ghrelin route

GHSR-1a is also a G protein-coupled receptor, but it mainly couples to Gq. When Ipamorelin binds, phospholipase C produces IP3 and DAG, calcium is released from internal stores, and protein kinase C is activated. The result is growth hormone release by a route that does not depend on cyclic AMP. GHSR-1a is also unusual in having high background activity even when nothing is bound.

Where the routes meet

Both pathways end in a rise in calcium inside the somatotroph, which is what triggers release. Because they get there by different routes, they can add together, and the ghrelin route is less affected by somatostatin. That is the molecular reason the two are studied together.

Why Ipamorelin left cortisol alone

Older ghrelin-receptor peptides raised ACTH and cortisol, partly through effects in the hypothalamus and pituitary corticotrophs. Ipamorelin’s structure appears to give it a much narrower effect, so that at growth hormone releasing doses it behaved more like GHRH than like GHRP-6 in those measures. The exact structural reason is still discussed.

Why Quality Control Looks Different for These Two

A 29-residue peptide and a 5-residue peptide fail in different ways during synthesis. For Sermorelin, the main risks are deletion sequences, where one of 29 amino acids failed to couple, and oxidation of its methionine. Many of those impurities have almost the same mass as the real peptide, so purity testing has to separate them carefully. For Ipamorelin, the risks are different: incorrect stereochemistry at its D-amino acids, or a failed coupling of one of its unusual residues. With only five amino acids, a single error produces a very different molecule.

How Crown Peptides verifies every batch

Every batch of Ipamorelin Research Peptide and Sermorelin Research Peptide is tested by HPLC for purity and mass spectrometry for identity. Certificates are published on our Lab Reports page, and our guide on how to read a peptide certificate of analysis explains each section. Both arrive as lyophilised powders. Our storage information and peptide reconstitution guide cover handling in the lab.

Handling in the lab

Both compounds are short and robust as peptides go, but neither is immune to the ordinary enemies of a peptide: heat, moisture and light. Lyophilised powders are at their most stable when kept cold, dry and away from light, so they should go into the fridge or freezer as soon as they arrive. Once a vial has been reconstituted, it should be kept refrigerated, drawn from with clean technique and used within the window set out in our peptide reconstitution guide. Repeated freezing and thawing of a solution is best avoided, because each cycle gives the chain another chance to break down or clump. Small habits like these protect the purity that the certificate describes, all the way from the vial to the experiment.

Related Compounds Across the Growth Hormone Axis

Other GHRH analogues

Tesamorelin is the full 44-amino-acid GHRH with a protective chemical group added, and became an approved medicine. CJC-1295 (With DAC) is a modified 29-amino-acid GHRH that binds albumin and lasts for days. For how those two compare, see Sermorelin vs Tesamorelin and CJC-1295 vs Sermorelin.

Other ghrelin-receptor peptides

GHRP-2 and GHRP-6 are the older, less selective relatives of Ipamorelin. Our comparisons Ipamorelin vs GHRP-2 and GHRP-6 vs Ipamorelin explain the differences.

Further down the axis

Growth hormone acts largely through IGF-1. IGF-1 LR3 is a long-acting IGF-1 analogue used to study that downstream step directly. For an overview of the whole family, see best peptides for muscle research.

Ipamorelin and Sermorelin Questions, Answered

Do Ipamorelin and Sermorelin act on the same receptor?

No. Sermorelin acts on the GHRH receptor, the same receptor as the brain’s own growth hormone releasing hormone. Ipamorelin acts on the ghrelin receptor, GHSR-1a. Both receptors sit on the same pituitary cells, which is why both compounds release growth hormone.

Is either of them growth hormone?

No. Neither contains growth hormone. Both are signals that ask the pituitary to release its own growth hormone, which is why the body’s feedback systems still apply to them.

Why is Sermorelin no longer sold as a medicine?

The branded version, Geref, was withdrawn from the US market for commercial reasons rather than because of safety findings. The compound itself remains well characterised, and it is widely used in research.

Which one has more human data?

Sermorelin, by some distance. It was a licensed treatment for children and was studied in older adults in the 1990s. Ipamorelin’s main human study was a phase 2 surgical trial in 114 patients, which found it well tolerated but not effective for its intended use.

Can Ipamorelin and Sermorelin be studied together?

Yes. Because they use different receptors, combining a GHRH analogue with a ghrelin-receptor agonist is a well-established experimental design in growth hormone research. Our guide to peptide stacking in research covers how researchers approach combined designs.

Why did the synthetic peptides come before ghrelin?

Because the growth hormone releasing peptides were discovered by testing compounds and watching what the pituitary did, not by starting from a known hormone. GHRP-6 was in use for over a decade before its receptor was cloned in 1996, and ghrelin, the natural hormone for that receptor, was found in 1999. Ipamorelin was introduced in 1998, right as that picture was coming together.

Are Ipamorelin and Sermorelin controlled in the UK?

Neither is listed under the Misuse of Drugs Act, and both can be bought for laboratory research. Our article are peptides legal in the UK explains the wider picture.

Where This Research Is Heading

Both halves of this comparison have moved forward in the clinic, even if these two particular molecules have not. On the GHRH side, Sermorelin’s direct descendant Tesamorelin became an approved medicine in the United States and has since been studied in fatty liver disease and brain ageing. On the ghrelin side, the receptor that Ipamorelin made famous became a real drug target: anamorelin, an oral ghrelin-receptor agonist, was approved in Japan for weight and muscle loss in cancer patients. Neither approval applies to Ipamorelin or Sermorelin themselves, but both show that the two pathways these compounds were built to probe are taken seriously by medicine.

That leaves plenty of open questions for laboratory research. How much of the benefit of a GHRH signal comes from pulse size, and how much from pulse timing? Can a ghrelin-receptor signal be tuned to favour growth hormone over appetite? How do the two pathways change with age, and do they age at the same rate? Ipamorelin and Sermorelin remain two of the cleanest tools for asking those questions, precisely because each one speaks for only one side of the conversation.

Two Signals, One Gland

Sermorelin is the brain’s own message, trimmed to its working core. Ipamorelin is a designed stand-in for a gut hormone that turned out to have a second job in the pituitary. Both make growth hormone, but they reach it by different receptors, different signals inside the cell and different relationships with the somatostatin brake.

That is what makes the comparison useful. Sermorelin answers questions about the GHRH pathway and comes with decades of clinical history. Ipamorelin answers questions about the ghrelin pathway and stands out for its selectivity. Together they let researchers study growth hormone release from both sides of the same cell. Both Ipamorelin Research Peptide and Sermorelin Research Peptide are available from Crown Peptides with batch-specific certificates, dispatched from the UK.